{'fraction_non_alphanumeric': 0.06492411467116357, 'fraction_numerical': 0.012647554806070826, 'mean_word_length': 4.734299516908212, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Leukocyte adherence inhibition (LAI) test, LAI. Trypsin and LAI. Humoral test in large term immunotherapy with levamisole on breast and colon cancer.

LAI test was studied in 231 patients, forming the following groups: "Presurgical", "Post surgical immediate", "Post surgical mediate", "Post surgical under treatment" (with levamisole) and "Metastasized". The following mean NAI were obtained: 65%, 40%, 48%, 0% and -13% respectively. On 149 patients LAI test, LAI trypsin test and Humoral LAI test were performed. The obtained values, allowed to develop five groups, according to the LAI and LAI Trypsin test positivity or negativity, i.e. group I: -,-; group II: +,-; group III: +,+; group IV: -,+; group V: -,-. A patient could pass through group I to V when he courses from a starting cancer to metastasis. Besides the action of conventional therapy, a low tumoral burden residual cancer could be treated with success by long term alternate therapy, with levamisole. Those cases showed that they run through the aforementioned groups from group V to I, remaining both LAI tests negative for years if immunotherapy's protocol is fulfilled. Moreover, an adequate follow-up is assured.